JPM24: BioMarin's new CEO Hardy says top priority is expansion of dwarfism drug Voxzogo
Fierce Pharma
JANUARY 10, 2024
In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist. | In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist.
233 
Let's personalize your content